Status:
RECRUITING
The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers
Lead Sponsor:
University of Athens
Conditions:
Smoking Cessation
Arterial Stiffness
Eligibility:
All Genders
18-75 years
Brief Summary
Introduction: Pharmacological interventions can enhance smoking cessation success and long-term abstinence. Cytisine, a plant derived alkaloid, is a selective partial agonist at alpha-4 beta-2 nicotin...
Detailed Description
Introduction Undoubtedly, smoking is one of the most important risk factors for cardiovascular diseases and smoking cessation is one of the most effective interventions for both primary and secondary ...
Eligibility Criteria
Inclusion
- Smokers willing to participate
Exclusion
- history of coronary artery disease, active malignancy, history of severe liver and renal failure, history of autoimmune disease.
Key Trial Info
Start Date :
November 12 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 10 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06885970
Start Date
November 12 2024
End Date
August 10 2025
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Attikkon University Hospital
Athens, Haidari, Greece, 12462